natgillin/translations-raw huggingface dataset:
All patients received study therapy as initial treatment for locally advanced or metastatic NSCLC and patients in both treatment groups were fully supplemented with folic acid and vitamin B12. 
Svi su bolesnici primali ispitivanu terapiju kao početnu terapiju za lokalno uznapredovali ili metastatski rak pluća nemalih stanica, a uz to su bolesnici u obje ispitivane skupine primali i potpuni nadomjestak folatne kiseline i vitamina B12.
50% of previous dose 
50% prethodne doze
Other undesirable effects include renal toxicities, increased aminotransferases, alopecia, fatigue, dehydration, rash, infection/sepsis and neuropathy. 
Ostale nuspojave uključuju bubrežnu toksičnost, povišene vrijednosti aminotransferaza, alopeciju, umor, dehidraciju, osip, infekciju/sepsu i neuropatiju.
Once in the cell, pemetrexed is rapidly and efficiently converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. 
Kad uđe u stanicu, pemetreksed se pod utjecajem enzima folilpoliglutamat sintetaze brzo i učinkovito pretvara u poliglutamatne oblike.
Pemetrexed can suppress bone marrow function as manifested by neutropenia, thrombocytopenia, and anaemia (or pancytopenia) (see section 4.8). 
Pemetreksed može suprimirati funkciju koštane srži, što se očituje neutropenijom, trombocitopenijom i anemijom (ili pancitopenijom) (vidjeti dio 4.8).
Women must use effective contraception during treatment with pemetrexed. 
Žene moraju primjenjivati djelotvornu kontracepciju tijekom liječenja pemetreksedom.
In patients with normal renal function (creatinine clearance ≥ 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen > 1600 mg/day) and acetylsalicylic acid at higher doses (≥ 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events. 
U bolesnika s normalnom funkcijom bubrega (klirens kreatinina ≥ 80 ml/min), visoke doze nesteroidnih protuupalnih lijekova (NSAIL, npr. ibuprofen > 1600 mg na dan) i više doze acetilsalicilatne kiseline (≥ 1,3 g na dan) mogu smanjiti eliminaciju pemetrekseda i, posljedično, povećati pojavu nuspojava izazvanih pemetreksedom.
Each vial contains an excess of pemetrexed to facilitate delivery of label amount. 
Jedna bočica sadrži pemetreksed u suvišku kako bi se olakšala primjena deklarirane količine lijeka.
Administration of pemetrexed to pregnant mice resulted in decreased foetal viability, decreased foetal weight, incomplete ossification of some skeletal structures, and cleft palate. 
Primjena pemetrekseda u gravidnih ženki miševa rezultirala je smanjenjem preživljenja i tjelesne težine ploda, nepotpunim okoštavanjem nekih koštanih struktura i pojavom rascjepa nepca.
Concomitant administration of nephrotoxic medicinal products (e.g., aminoglycoside, loop diuretics, platinum compounds, ciclosporin) could potentially result in delayed clearance of pemetrexed. 
Istodobna primjena s nefrotoksičnim lijekovima (npr. aminoglikozidom, diureticima Henleove petlje, spojevima platine, ciklosporinom) može rezultirati odgođenim klirensom pemetrekseda.
• If you experience bleeding from the gums, nose or mouth or any bleeding that would not stop, reddish or pinkish urine, unexpected bruising (since you might have less platelets than normal which is very common). 
• ako imate krvarenje iz desni, nosa ili usta ili bilo kakvo krvarenje koje ne prestaje, crvenkastu ili ružičastu boju mokraće, neočekivane modrice (jer broj krvnih pločica može biti manji od normalnog, što je vrlo česta pojava)
Adenocarcinom a (N = 847) 
Adenokarcinom (N = 847)
Children and adolescents There is no relevant use of pemetrexed in the paediatric population. 
Nema relevantne primjene pemetrekseda u pedijatrijskoj populaciji.
Pemetrexed must only be administered under the supervision of a physician qualified in the use of anti-cancer chemotherapy. 
Pemetreksed se smije primjenjivati samo pod nadzorom liječnika koji je obučen za primjenu antitumorske kemoterapije.
Limited clinical data from a separate randomised, Phase-3, controlled trial, suggest that efficacy data (overall survival, progression-free survival) for pemetrexed are similar between patients previously pre-treated with docetaxel (N = 41) and patients who did not receive previous docetaxel treatment (N = 
Ograničeni klinički podaci iz zasebnog randomiziranog kontroliranog ispitivanja faze III ukazuju na to da su podaci o djelotvornosti (ukupno preživljenje, preživljenje bez progresije bolesti) za pemetreksed podjednaki u bolesnika prethodno liječenih docetakselom (N = 41) i bolesnika koji prethodno nisu primali docetaksel (N = 540).
The separation between the treatment arms was achieved by improvement in lung function in the pemetrexed /cisplatin arm and deterioration of lung function over time in the control arm. 
Skupine su se razlikovale i po tome što se u bolesnika liječenih kombinacijom pemetreksed/cisplatin funkcija pluća poboljšala, dok se u kontrolnoj skupini s vremenom pogoršavala.
A hospital pharmacist, nurse or doctor will have mixed the Pemetrexed Pfizer powder with water for injections and 5% glucose solution for injection before it is given to you. 
Prije primjene lijeka Pemetreksed Pfizer bolnički ljekarnik, medicinska sestra ili liječnik će pomiješati Pemetreksed Pfizer prašak s vodom za injekcije i 5%-tnom otopinom glukoze za injekciju.
Efficacy of pemetrexed + cisplatin vs. gemcitabine + cisplatin in first-line non-small cell lung cancer - ITT population and histology subgroups 
Djelotvornost pemetrekseda + cisplatina u odnosu na gemcitabin + cisplatin u prvoj liniji liječenja raka pluća nemalih stanica - ITT populacija i podskupine prema histološkom tipu
During post-marketing surveillance, the following adverse reactions have been reported in patients treated with pemetrexed: 
Tijekom praćenja nakon stavljanja lijeka u promet u bolesnika liječenih pemetreksedom prijavljene su sljedeće nuspojave:
Pemetrexed undergoes limited hepatic metabolism. 
Pemetreksed podliježe ograničenom jetrenom metabolizmu.
Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size. 
Kratice: CI = interval pouzdanosti; ITT = populacija s namjerom liječenja; N = ukupan broj bolesnika.
Clinically relevant Grade 3 and Grade 4 laboratory toxicities were similar between integrated Phase 2 results from three single-agent pemetrexed studies (N = 164) and the Phase 3 single-agent pemetrexed study described above, with the exception of neutropenia (12.8% versus 5.3%, respectively) and alanine aminotransferase elevation (15.2% versus 1.9%, respectively). 
Klinički značajni oblici toksičnosti stupnja 3 i 4 utvrđeni laboratorijskim pretragama bili su podjednaki u objedinjenim rezultatima triju ispitivanja faze II pemetrekseda u monoterapiji (N = 164) i rezultatima gore opisanog kliničkog ispitivanja faze III pemetrekseda u monoterapiji, s iznimkom neutropenije (12,8% naspram 5,3%) i povišenih vrijednosti alanin aminotransferaze (15,2% naspram 1,9%).
Patients must receive adequate anti-emetic treatment and appropriate hydration prior to and/or after receiving cisplatin (see also cisplatin Summary of Product Characteristics for specific dosing advice). 
Prije i/ili nakon primjene cisplatina bolesnici moraju primiti odgovarajući antiemetik i primjerenu hidrataciju (vidjeti i posebne preporuke za doziranje u sažetku opisa svojstava lijeka za cisplatin).
These differences were likely due to differences in the patient population, since the Phase 2 studies included both chemonaive and heavily pre-treated breast cancer patients with pre-existing liver metastases and/or abnormal baseline liver function tests. 
Te su razlike vjerojatno posljedica razlika između populacija bolesnika, s obzirom da su u ispitivanja faze II bile uključene i bolesnice s rakom dojke koje prethodno nisu primale kemoterapiju i one koje su prethodno primale više linija terapije i imale metastaze u jetri i/ili abnormalne vrijednosti jetrenih enzima na početku ispitivanja.
Women of childbearing potential must use effective contraception during treatment with pemetrexed. 
Žene reproduktivne dobi moraju koristiti učinkovitu kontracepciju tijekom liječenja pemetreksedom.
If you have had or are going to have radiation therapy, please tell your doctor, as there may be an early or late radiation reaction with Pemetrexed Pfizer. 
Ako ste primali ili ćete primati terapiju zračenjem, obavijestite o tome svog liječnika jer se uz primjenu lijeka Pemetreksed Pfizer mogu pojaviti rane ili kasne reakcije na zračenje.
However, patients with hepatic impairment, such as bilirubin > 1.5times the upper limit of normal and/or aminotransferase > 3.0-times the upper limit of normal (hepatic metastases absent) or > 5.0 times the upper limit of normal (hepatic metastases present), have not been specifically studied. 
Međutim, nisu posebno ispitivani bolesnici s oštećenjem jetre u kojih je vrijednost bilirubina bila > 1,5 puta iznad gornje granice normale i/ili vrijednost aminotransferaza > 3,0 puta iznad gornje granice normale (bez metastaza u jetri) odnosno > 5,0 puta iznad gornje granice normale (uz metastaze u jetri).
The PFS and OS results in patients with squamous cell histology suggested no advantage for pemetrexed over placebo. 
Rezultati PFS-a i ukupnog preživljenja u bolesnika s rakom pluća skvamoznih stanica nisu pokazali prednost pemetrekseda nad placebom.
If patients develop non-haematologic toxicities ≥ Grade 3 (excluding neurotoxicity), pemetrexed should be withheld until resolution to less than or equal to the patient's pre-therapy value. 
Razvije li se u bolesnika nehematološka toksičnost stupnja ≥ 3 (osim neurotoksičnosti), primjena pemetrekseda mora se prekinuti dok se vrijednosti ne vrate na razinu prije liječenja ili nižu.
Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. 
Pemetreksed se u stanice prenosi i nosačima reduciranih folata i prijenosnim sustavom membranskih proteina koji vežu folate.
Uncommon cases of acute renal failure have been reported with pemetrexed alone or in association with other chemotherapeutic agents (see section 4.4). 
Slučajevi akutnog zatajenja bubrega prijavljeni su manje često pri primjeni pemetrekseda samog ili u kombinaciji s drugim kemoterapeuticima (vidjeti dio 4.4).
Pemetrexed Pfizer is also given in combination with cisplatin for the initial treatment of patients with advanced stage of lung cancer. 
Pemetreksed Pfizer se također primjenjuje u kombinaciji s cisplatinom za početno liječenje bolesnika s uznapredovalim stadijem raka pluća.
The appropriate volume of reconstituted pemetrexed solution must be further diluted to 100 ml with 5% glucose solution for injection, without preservative, and administered as an intravenous infusion over 10 minutes. 
Odgovarajući volumen rekonstituirane otopine pemetrekseda mora se dodatno razrijediti 5%-tnom otopinom glukoze za injekciju, bez konzervansa, do ukupnog volumena od 100 ml i primijeniti kao intravenska infuzija tijekom 10 minuta.
Pemetrexed is a multi-targeted anti-cancer antifolate agent that exerts its action by disrupting crucial folate-dependent metabolic processes essential for cell replication. 
Pemetreksed je protutumorski lijek s višestrukim antifolatnim djelovanjem koji djeluje tako da prekida ključne metaboličke procese ovisne o folatima neophodne za umnažanje stanica.
Patients should be monitored for myelosuppression during therapy and pemetrexed should not be given to patients until absolute neutrophil count (ANC) returns to ≥ 1,500 cells/mm3 and platelet count returns to ≥ 100,000 cells/mm3. 
U bolesnika se tijekom liječenja moraju pratiti pokazatelji mijelosupresije i pemetreksed se ne smije davati sve dok apsolutni broj neutrofila (ABN) ne bude ≥ 1500 stanica/mm a broj trombocita ≥ 100 000 stanica/mm
Upon recovery, patients should be re-treated using the guidelines in Tables 1, 2, and 3, which are applicable for pemetrexed used as a single agent or in combination with cisplatin. 
Nakon oporavka bolesnika treba ponovno liječiti prema smjernicama za primjenu pemetrekseda u monoterapiji ili u kombinaciji s cisplatinom, prikazanima u Tablicama 1, 2 i 3.
The pharmacokinetic properties of pemetrexed following single-agent administration have been evaluated in 426 cancer patients with a variety of solid tumours at doses ranging from 0.2 to 
Farmakokinetička svojstva pemetrekseda nakon primjene u monoterapiji ispitana su u 426 onkoloških bolesnika s različitim solidnim tumorima, pri dozama od 0,2 do 838 mg/m2 primijenjenima u infuziji tijekom 10 minuta.
Efficacy of pemetrexed vs. docetaxel in NSCLC - ITT population pemetrexed docetaxel 
Djelotvornost pemetrekseda u odnosu na docetaksel kod NSCLC - ITT populacija Pemetreksed
Cases of radiation pneumonitis have been reported in patients treated with radiation either prior, during, or subsequent to their pemetrexed therapy. 
Prijavljeni su slučajevi radijacijskog pneumonitisa u bolesnika koji su prije, tijekom ili poslije terapije pemetreksedom liječeni zračenjem.
Rare cases of radiation recall have been reported in patients who have received radiotherapy previously (see section 4.4). 
Slučajevi odzivne radijacijske upalne reakcije (engl. radiation recall) prijavljeni su rijetko u bolesnika koji su prethodno liječeni radioterapijom (vidjeti dio 4.4).
As with other potentially toxic anti-cancer agents, care should be exercised in the handling and preparation of pemetrexed infusion solutions. 
Kao i kod svih potencijalno toksičnih protutumorskih lijekova, potreban je oprez pri rukovanju i pripremi otopine pemetrekseda za infuziju.
Pemetrexed Pfizer is for intravenous use. 
Pemetreksed Pfizer namijenjen je za intravensku primjenu.
Pemetrexed is physically incompatible with diluents containing calcium, including lactated Ringer's injection and Ringer's injection. 
Pemetreksed je fizikalno inkompatibilan s otapalima koja sadrže kalcij, uključujući otopinu Ringerovog laktata i Ringerovu otopinu za infuziju.
**Refer to NCI CTCAE Criteria (Version 3.0; NCI 2003) for each grade of toxicity. 
**Za sve stupnjeve toksičnosti vidjeti NCI CTCAE (verzija 3.0; NCI 2003).
The use of calcium folinate/folinic acid in the management of pemetrexed overdose should be considered. 
U liječenju predoziranja pemetreksedom potrebno je razmotriti primjenu kalcijeva folinata/folinatne kiseline.
Pemetrexed in combination with cisplatin 
Pemetreksed u kombinaciji s cisplatinom
Serious renal events, including acute renal failure, have been reported with pemetrexed alone or in association with other chemotherapeutic agents. 
Ozbiljni bubrežni događaji, uključujući akutno zatajenje bubrega, zabilježeni su pri primjeni pemetrekseda samog ili u kombinaciji s drugim kemoterapeuticima.
The recommended dose of cisplatin is 75 mg/m2 BSA infused over two hours approximately 30 minutes after completion of the pemetrexed infusion on the first day of each 21-day cycle. 
Preporučena doza cisplatina je 75 mg/m2 tjelesne površine, a primjenjuje se infuzijom u trajanju od dva sata, približno 30 minuta nakon završetka infuzije pemetrekseda, prvog dana svakog 21-dnevnog ciklusa.
A subgroup analysis was performed on patients who received folic acid and vitamin B12 supplementation during the entire course of study therapy (fully supplemented). 
Provedena je analiza podskupine bolesnika koji su za cijelog trajanja liječenja u ispitivanju primali nadomjestak folatne kiseline i vitamina B12 (potpun nadomjestak).
Reported symptoms of overdose include neutropenia, anaemia, thrombocytopenia, mucositis, sensory polyneuropathy, and rash. 
Prijavljeni simptomi predoziranja uključuju neutropeniju, anemiju, trombocitopeniju, mukozitis, senzornu polineuropatiju i osip.
All patients were diagnosed with Stage IIIB or IV NSCLC and had received prior platinum-based chemotherapy. 
Svi su bolesnici imali dijagnozu raka pluća nemalih stanica stadija IIIB ili IV i prethodno su primali kemoterapiju na bazi platine.
Pre-medication regimen 
Protokol za premedikaciju
A Phase 2 study of pemetrexed in 31 solid tumour patients with stable third-space fluid demonstrated no difference in pemetrexed dose normalised plasma concentrations or clearance compared to patients without third-space fluid collections. 
U ispitivanju pemetrekseda faze II u 31 bolesnika sa solidnim tumorom i stabilnom tekućinom u transcelularnom prostoru nije uočena razlika u koncentracijama pemetrekseda u plazmi normaliziranima za dozu, kao ni u klirensu pemetrekseda, u usporedbi s bolesnicima koji nisu imali nakupljanje tekućine u transcelularnom prostoru.
Efficacy parameter pemetrexed / cisplatin (N = 226) 
Parametar djelotvornosti pemetreksed / cisplatin (N = 226)
The median time from the start of pemetrexed plus cisplatin induction therapy to the start of maintenance treatment was 2.96 months on both the pemetrexed arm and the placebo arm. Randomised patients received maintenance treatment until disease progression. 
Medijan vremena od početka uvodnog liječenja pemetreksedom i cisplatinom do početka terapije održavanja iznosio je 2,96 mjeseci i u skupini koja je primala pemetreksed i u skupini koja je primala placebo.
Progression-free survival (PFS) and overall response rate were similar between treatment arms: median PFS was 4.8 months for pemetrexed plus cisplatin versus 5.1 months for gemcitabine plus cisplatin (adjusted hazard ratio (HR) 1.04; 95% CI= 0.94-1.15), and overall response rate was 30.6% (95% CI= 27.3- 33.9) for pemetrexed plus cisplatin versus 28.2% (95% CI= 25.0-31.4) for gemcitabine plus cisplatin. 
Preživljenje bez progresije bolesti (engl. progression-free survival, PFS) i stopa ukupnog odgovora bili su podjednaki između terapijskih skupina: medijan PFS-a iznosio je 4,8 mjeseci za pemetreksed i cisplatin u usporedbi s 5,1 mjeseci za gemcitabin i cisplatin (prilagođen omjer hazarda 1,04; 95% CI = 0,94 - 1,15), a stopa ukupnog odgovora bila je 30,6% (95% CI = 27,3 - 33,9) za pemetreksed i cisplatin u usporedbi s 28,2% (95% CI = 25,0 - 31,4) za gemcitabin i cisplatin.
Reconstituted and infusion solutions 
Rekonstituirana otopina i otopina za infuziju
Metabolism and nutrition disorders 
Poremećaji metabolizma i prehrane često dehidracija
The most commonly reported undesirable effects related to pemetrexed, whether used as monotherapy or in combination, are bone marrow suppression manifested as anaemia, neutropenia, leucopenia, thrombocytopenia; and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis. 
Najčešće prijavljene nuspojave povezane s primjenom pemetrekseda, kako u monoterapiji tako i u kombinaciji s drugim lijekovima, su supresija koštane srži, koja se očituje kao anemija, neutropenija, leukopenija, trombocitopenija; i gastrointestinalna toksičnost, koja se očituje kao anoreksija, mučnina, povraćanje, proljev, konstipacija, faringitis, mukozitis i stomatitis.
Patients also required lower administration of erythropoietin/darbopoietin (10.4% versus 18.1%, p < 0.001), G-CSF/GM-CSF (3.1% versus 6.1%, p = 0.004), and iron preparations (4.3% versus 7.0%, p = 0.021). 
U tih je bolesnika također rjeđe trebalo primijeniti eritropoetin/darbepoetin (10,4% naspram 18,1%, p < 0,001), G-CSF/GM-CSF (3,1% naspram 6,1%, p = 0,004) i pripravke željeza (4,3% naspram 7,0%, p = 0,021).
Uncommon cases of radiation pneumonitis have been reported in patients treated with radiation either prior, during or subsequent to their pemetrexed therapy (see section 4.4). 
Slučajevi radijacijskog pneumonitisa prijavljeni su manje često u bolesnika koji su liječeni radioterapijom prije, tijekom ili nakon terapije pemetreksedom (vidjeti dio 4.4).
There are limited data in patients with malignant pleural mesothelioma treated with pemetrexed alone. 
Podaci o bolesnicima s malignim pleuralnim mezoteliomom liječenima samo pemetreksedom su ograničeni.
Patients receiving pemetrexed should be monitored before each dose with a complete blood count, including a differential white cell count (WCC) and platelet count. 
U bolesnika koji primaju pemetreksed prije svake se doze mora provesti kontrola kompletne krvne slike, uključujući i diferencijalnu krvnu sliku (DKS) te broj trombocita.
Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4% versus 28.9%, p < 0.001), red blood cell transfusions (16.1% versus 27.3%, p < 0.001) and platelet transfusions (1.8% versus 4.5%, p =0.002). 
Bolesnici liječeni pemetreksedom i cisplatinom trebali su manje transfuzija (16,4% naspram 28,9%, p < 0,001), transfuzija eritrocita (16,1% naspram 27,3%, p < 0,001) i transfuzija trombocita (1,8% naspram 4,5%, p = 0,002).
Pemetrexed Pfizer is given in combination with cisplatin, another anti-cancer medicine, as treatment for malignant pleural mesothelioma, a form of cancer that affects the lining of the lung, to patients who have not received prior chemotherapy. 
Pemetreksed Pfizer se primjenjuje u kombinaciji s cisplatinom, još jednim protutumorskim lijekom, za liječenje zloćudnog pleuralnog mezotelioma, oblika raka koji zahvaća plućne ovojnice, u bolesnika koji prethodno nisu primali kemoterapiju.
There were no clinically relevant differences observed for the safety profile of pemetrexed within the histology subgroups. 
Nisu uočene klinički značajne razlike u sigurnosnom profilu pemetrekseda unutar podskupina prema histološkom tipu.
Median time to tumour progression (months) (95% CI) 
Medijan vremena do progresije tumora (mjeseci) (95% CI)
Pemetrexed was not mutagenic in either the in vitro chromosome aberration test in Chinese hamster ovary cells, or the Ames test. Pemetrexed has been shown to be clastogenic in the in vivo micronucleus test in the mouse. 
Ni in vitro ispitivanje kromosomskih aberacija u stanicama jajnika kineskoga hrčka, niti Amesov test nisu ukazali na mutageni učinak pemetrekseda.
All patients were diagnosed with locally advanced or metastatic non-small cell lung cancer and received prior chemotherapy. 
Svi su bolesnici imali lokalno uznapredovali ili metastatski rak pluća nemalih stanica i prethodno su primali kemoterapiju.
In the absence of data regarding potential interaction with NSAIDs having longer half-lives such as piroxicam or rofecoxib, the concomitant administration with pemetrexed in patients with mild to moderate renal insufficiency should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration (see section 4.4). 
U nedostatku podataka o mogućim interakcijama s NSAIL s duljim poluvijekom, poput piroksikama ili rofekoksiba, u bolesnika s blagim do umjerenim zatajenjem bubrega, njihova se istodobna primjena mora prekinuti najmanje pet dana prije, na sam dan i najmanje dva dana nakon primjene pemetrekseda (vidjeti dio 4.4).
The following information is intended for healthcare professionals only: Instructions for use, handling and disposal 
Sljedeće informacije namijenjene su samo zdravstvenim radnicima:
METHOD OF ADMINISTRATION Reconstitute and dilute before use See leaflet. 
Rekonstituirati i razrijediti prije primjene.
Patients in both study arms were fully supplemented with folic acid and vitamin B12. 
Bolesnici u obje ispitivane skupine primali su potpun nadomjestak folatne kiseline i vitamina B12.
In clinical trials, cases of colitis (including intestinal and rectal bleeding, sometimes fatal, intestinal perforation, intestinal necrosis and typhlitis) have been reported uncommonly in patients treated with pemetrexed. 
Tijekom kliničkih ispitivanja manje su često prijavljeni slučajevi kolitisa (uključujući intestinalno i rektalno krvarenje, koje je ponekad bilo smrtonosno, perforaciju crijeva, nekrozu crijeva i tiflitis) u bolesnika liječenih pemetreksedom.
• If you experience tiredness, feeling faint, becoming easily breathless or if you look pale (since you might have less haemoglobin than normal which is very common). 
• ako osjetite umor, nesvjesticu, nedostatak zraka ili ste blijedi (jer razina hemoglobina može biti niža od normalne, što je vrlo česta pojava)
Pharmacotherapeutic group: antineoplastic agents, folic acid analogues. 
Farmakoterapijska skupina: Antineoplastici, analog folatne kiseline, ATK oznaka: L01BA04